Clinical impact of omalizumab in refractory chronic urticaria: One centre experience

  • Authors:
    • Diana Deleanu
    • Irena Nedelea
    • Carina Petricau
    • Poliana Leru
    • Dinu Dumitrascu
    • Adriana Muntean
  • View Affiliations

  • Published online on: October 24, 2019     https://doi.org/10.3892/etm.2019.8126
  • Pages: 5078-5081
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Chronic spontaneous urticaria is a debilitating disorder, which has a major impact on the quality of life of affected individuals, and is a substantial global burden. Refractory, difficult to treat cases pose a difficult challenge to patients and clinicians alike. Advances in the field of immunotherapy have led to novel and effective therapeutic strategies. Omalizumab, an immunomodulatory anti-IgE monoclonal antibody, inaugurated a new era in the treatment of refractory chronic urticaria. Several multicenter clinical trials have proven omalizumab to be a safe and effective option for the treatment of refractory symptoms of chronic spontaneous urticaria, while some small studies have shown its efficacy in chronic inductible urticaria as well. In this study, we bring forth updates in chronic urticaria approach, with a focus on our experience with anti-IgE therapy in different forms of chronic urticaria treated at the Allergy Department of the Professor Doctor Octavian Fodor Regional Institute of Gastroenterology and Hepatology (Cluj-Napoca, Romania).
View References

Related Articles

Journal Cover

December 2019
Volume 18 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Deleanu, D., Nedelea, I., Petricau, C., Leru, P., Dumitrascu, D., & Muntean, A. (2019). Clinical impact of omalizumab in refractory chronic urticaria: One centre experience. Experimental and Therapeutic Medicine, 18, 5078-5081. https://doi.org/10.3892/etm.2019.8126
MLA
Deleanu, D., Nedelea, I., Petricau, C., Leru, P., Dumitrascu, D., Muntean, A."Clinical impact of omalizumab in refractory chronic urticaria: One centre experience". Experimental and Therapeutic Medicine 18.6 (2019): 5078-5081.
Chicago
Deleanu, D., Nedelea, I., Petricau, C., Leru, P., Dumitrascu, D., Muntean, A."Clinical impact of omalizumab in refractory chronic urticaria: One centre experience". Experimental and Therapeutic Medicine 18, no. 6 (2019): 5078-5081. https://doi.org/10.3892/etm.2019.8126